| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Entrez GeneID | 567 |
| clone | 3G5H8 |
| WB Predicted band size | 13.7kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human B2M (AA: 21-100) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于B2M(β-2微球蛋白)抗体的示例参考文献及摘要概括(文献为模拟示例，建议通过学术数据库查询具体研究)：
---
1. **"Targeting B2M in cancer immunotherapy: mechanisms and therapeutic potential"**
*作者：Smith A, et al.*
**摘要**：探讨了B2M在肿瘤免疫逃逸中的作用，研究通过靶向B2M的抗体阻断MHC-I分子功能，增强T细胞对肿瘤细胞的杀伤效果，为实体瘤免疫治疗提供新策略。
2. **"Anti-B2M monoclonal antibody reverses drug resistance in multiple myeloma"**
*作者：Chen L, et al.*
**摘要**：发现B2M过表达与多发性骨髓瘤化疗耐药相关，开发的特异性抗B2M单抗可抑制肿瘤细胞增殖并恢复其对化疗药物的敏感性。
3. **"B2M as a biomarker in autoimmune diseases: implications for antibody-based diagnostics"**
*作者：Wang Y, et al.*
**摘要**：分析B2M在类风湿性关节炎等自身免疫病患者血清中的水平，提出基于抗B2M抗体的检测方法可辅助疾病早期诊断和活动性监测。
4. **"Engineering a bispecific antibody targeting B2M and PD-1 for enhanced antitumor immunity"**
*作者：Zhang R, et al.*
**摘要**：设计双特异性抗体同时靶向B2M和PD-1.在小鼠模型中验证其协同激活T细胞、抑制肿瘤生长的效果，为联合免疫治疗提供新思路。
---
建议通过 **PubMed、Web of Science** 或 **Google Scholar** 检索关键词(如"B2M antibody"、"β-2 microglobulin therapy")获取最新具体文献。
Beta-2 microglobulin (B2M), a 12 kDa protein, is a non-polymorphic component of the major histocompatibility complex (MHC) class I molecules, essential for antigen presentation to cytotoxic T cells. It forms the light chain of MHC-I, stabilizing its structure and enabling immune recognition of pathogens or abnormal cells. Beyond its immunological role, B2M is constitutively expressed on nucleated cells and freely circulates in bodily fluids, with serum levels influenced by glomerular filtration. Elevated B2M levels are clinically linked to renal dysfunction, inflammatory disorders, and malignancies like multiple myeloma, where it serves as a prognostic biomarker.
In cancer biology, B2M loss or mutations are associated with immune evasion, as impaired MHC-I expression allows tumor cells to escape T-cell surveillance. This has spurred interest in B2M-targeting antibodies for immunotherapy. Anti-B2M antibodies are being explored to modulate immune responses—either by blocking MHC-I to suppress autoimmune reactions or by enhancing antigen presentation in tumors. Additionally, B2M-targeting CAR-T cells and antibody-drug conjugates (ADCs) are under investigation for hematologic cancers.
In neurodegenerative diseases, B2M aggregates contribute to dialysis-related amyloidosis, driving research into antibodies that clear pathologic B2M deposits. Despite promise, challenges like on-target/off-tumor toxicity and resistance mechanisms require further optimization. Overall, B2M antibodies represent a versatile tool bridging diagnostics, immune modulation, and targeted therapies.
×
